Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 StudyGlobeNewsWire • 07/24/24
Bears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' NowZacks Investment Research • 05/24/24
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024GlobeNewsWire • 05/09/24
Notable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 04/19/24
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024GlobeNewsWire • 04/09/24
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the PlatformGlobeNewsWire • 04/08/24
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided EnrollmentGlobeNewsWire • 02/22/24
Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial OutcomeGlobeNewsWire • 12/18/23
Notable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic SyndromesPRNewsWire • 12/13/23
Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMMLGlobeNewsWire • 11/09/23